Objective: To investigate the predictive value of platelet doubling (platelet count doubling) after one course of hypomethylating agents (HMA) on the treatment response and efficacy of myelodysplastic syndrome (MDS).
Methods: Clinical and pathological data of 75 patients who received HMA in our hospital from January 2017 to March 2022 were collected and analyzed. All patients were divided into two groups according to whether their platelet count doubled after one course of treatment, including platelet doubling group and non-doubling group, and statistical analysis was performed to compare the treatment response and efficacy between the two groups. In addition, platelet count changes were compared between azacitidine and decitabine therapy.
Results: Compared with the non-doubling platelet count group, the ORR of the doubling platelet group was significantly better after 3 courses of treatment ( =0.002), and there was a statistically significant difference in the number of HI between the two groups ( =0.005). In addition, the median survival time (MST) was 26 months in the platelet doubling group and 11 months in the non-doubling group ( =0.001). The overall survival (OS) and 1- and 2-year survival rates of the platelet doubling group were also significantly better than those of the non-doubing group. Multivariate COX analysis showed that platelet count doubling was an independent predictor of OS in MDS patients after 1 course of treatment ( =0.013). There was no significant difference in the response rate of platelet count doubling between MDS patients treated with azacitidine and decitabine (33.3% 23.8%, >0.05).
Conclusion: Platelet count doubling after one course of treatment can be used as a predictor of response rate and survival of demethylated drug therapy in MDS patients. In addition, there was no significant difference in the response rate of platelets in MDS patients treated with azacitidine or dicetabine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2024.01.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The clinical features and outcomes of elderly patients with acute myeloid leukemia: a real word research.
Clin Exp Med
January 2025
Medical Center of Hematology, Xinqiao Hospital of Army Medical University; Chongqing Key Laboratory of Hematology and Microenvironment; State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing, No.83 Xinqiao Main Street, Shapingba District, 400037, China.
The aim of this study was to investigate the clinical features and outcomes of elderly patients with acute myeloid leukemia (AML) from a real word research. The clinical data of 223 consecutive elderly patients (aged ≥ 60 years) who were newly diagnosed with AML at our medical center between July 2017 and June 2022, including their clinical characteristics, genetic mutations, and survival outcomes, were retrospectively analyzed. Among the 223 patients (median age 67 years), 180 (80.
View Article and Find Full Text PDFOptimization of the Use of APRI and FIB-4 for Ruling Out Liver Cirrhosis in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase.
J Viral Hepat
February 2025
Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
The exclusion of cirrhosis is important in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT). We aimed to optimise the performance of the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4) to exclude cirrhosis in these patients. Five hundred and eighty four patients with normal ALT who underwent liver biopsy were included in the study.
View Article and Find Full Text PDFRelationship between hypertensive disease stages of pregnancy and plateletcrit values: A retrospective cohort study.
Heliyon
November 2024
Republic of Türkiye Ministry of Health, Basaksehir Cam and Sakura City Hospital, Department of Obstetrics and Gynecology, Istanbul, Türkiye.
Objective: The aim of this study was to investigate the correlation between plateletcrit (PCT) and stages of hypertensive disease of pregnancy by comparing values in groups with healthy pregnancies, gestational hypertension [GHT], preeclampsia with proteinuria [PE + P] and severe preeclampsia with proteinuria [sPE + P]. The secondary aim was to investigate how proteinuria affects PCT values in these patients.
Materials And Methods: This was a retrospective cohort study.
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
Cancer
January 2025
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Introduction: The prognosis of relapsed or refractory mature T- and natural killer (NK)-cell lymphoma remains dismal. Novel agents are urgently needed to improve the outcomes for this population.
Methods: In this phase 2, multicenter, open-label, single-arm study (NCT03776279), the authors report the efficacy and safety of liposomal mitoxantrone (Lipo-MIT) monotherapy in patients with relapsed or refractory mature T- and NK-cell lymphoma.
Neutrophil-to-lymphocyte ratio as a predictor for early mortality in older patients requiring hemodialysis; insights for hemodialysis access planning.
BMC Nephrol
January 2025
Department of Laboratory Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea.
Introduction: The 2019 Kidney Disease Outcome Quality Initiative guidelines emphasize the importance of selecting dialysis based on the life expectancy of the patient. However, it is difficult to predict the life expectancy of a patient during arteriovenous fistula creation. We investigated whether neutrophil-to-lymphocyte, monocyte-to-lymphocyte, and platelet-to-lymphocyte ratios measured before dialysis could predict mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!